Effects of resolving phlegm method on fibrinolytic status in non-alcoholic steatohepatitis patients of phlegm and blood-stasis syndrome.
- Author:
Li CHEN
1
;
Yang-Kun JIANG
;
Yan-Bo CAI
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Blood Glucose; metabolism; Diagnosis, Differential; Drugs, Chinese Herbal; therapeutic use; Fatty Liver; blood; diagnosis; drug therapy; Female; Humans; Insulin; blood; Liver; drug effects; pathology; physiopathology; Male; Medicine, Chinese Traditional; methods; Middle Aged; Phytotherapy; Plasminogen Activator Inhibitor 1; metabolism; Syndrome; Tissue Plasminogen Activator; metabolism
- From: Chinese Journal of Integrated Traditional and Western Medicine 2006;26(12):1090-1093
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the effect of resolving phlegm method (RPM) on fibrinolytic status in non-alcoholic steatohepatitis (NASH) patients of phlegm blood-stasis (PBS) syndrome type.
METHODSSixty-two patients were randomly assigned to 2 groups, namely the treated group (n = 34) treated with Chinese herbs for resolving phlegm and dampness, smoothing liver and gallbladder, promoting blood circulation and removing blood stasis (composition: Indigo Naturalis 10 g, Alumen 3 g, Semen Cassiae 15 g, Fructus Crataegi 15 g, vinegar prepared Radix Bupleuri 10 g, Radix Curcumae 10 g, Radix Salviae Miltiorrhizae 12 g, Herba Lycopi 12 g, talc 12 g and Radix Glycyrrhizae 2 g), one dose twice per day orally, and the control group (n = 28) with ursodeoxycholic acid tablet (UAT) 150 mg three times per day. The treatment course for both groups was 12 weeks. Liver function (ALT, AST, ALP), insulin resistance (IR) index represented by homeostasis model-IR (HOMA-IR) and insulin (Ins), levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1), as well as main symptoms and physical signs were assessed before and after treatment.
RESULTS(1) Compared with those before treatment, levels of ALT, AST, HOMA-IR, t-PA, PAl-1 and main symptoms were all improved in the treated group (P < 0.05 or P < 0.01); (2) There was significant difference in ALP, HOMA-IR, t-PA and PAI-1 between the treated group and the control group (P < 0.05 or P < 0.01); (3) The improvement in liver function related indexes in the control group was mainly the level of ALT, t-PA (P < 0.01), and also shown on HOMA-IR, Ins and PAI-1.
CONCLUSIONRPM could effectively improve liver function and fibrinolytic status. Its effect was better than that of UAT.